CN103190609A - Food composition having function of weight reduction - Google Patents
Food composition having function of weight reduction Download PDFInfo
- Publication number
- CN103190609A CN103190609A CN2012102086347A CN201210208634A CN103190609A CN 103190609 A CN103190609 A CN 103190609A CN 2012102086347 A CN2012102086347 A CN 2012102086347A CN 201210208634 A CN201210208634 A CN 201210208634A CN 103190609 A CN103190609 A CN 103190609A
- Authority
- CN
- China
- Prior art keywords
- diet product
- product constituent
- weight
- loss
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a food composition having a function of weight reduction. The food composition is characterized in that the food composition comprises lactobacillus plantarum and wild-type glycostate; the lactobacillus plantarum is preserved in the Germany DSMZ strain preservation center, has a preservation address of Inhoffenstra beta e 7B, 38124Braunschweig, GERMANY, has a preservation date of July 15, 2010, and has the preservation number of DSM 23780. An animal test on the food composition proves that lactic acid bacteria in a mice intestinal tract can promote growth, improve concentrations of cholesterol and triglyceride in blood, obviously reduce leptin content, adipose tissue weight and cell volume, obviously improve blood lipid and regulate the intestinal tract.
Description
Technical field
The present invention is relevant with the diet product constituent with loss of weight function, refers to a kind of diet product constituent of being made up of lactobacillus germ (Lactobacillus plantarum) and wild type dioecism momordica root extract (Glycostate) especially.
Background technology
The at present commercially available main demand of lactic acid bacteria product is whole intestines and allergy, also there is part manufacturer to declare that lactic acid bacteria has fat-reducing effect in recent years, but there is no the experimental data evidence of actual tool public credibility research unit, mostly represent mode with star or the common people and market in society.In addition, commercially available lactic acid bacteria product all has other healthy food compositions of collocation, for example: natural goods compositions such as camellia, green tea, chitin, aloe, red colouring agent for food, also used as a Chinese medicine or oligosaccharides, in order to strengthen the effect of demand function, but the effective active components in this compound prescription is as the reciprocation of medicine, competition and inhibitory action also can take place, and may cause the product effect to strengthen, weaken, even invalid situation.
Moreover, unusual blood fat fat is to cause one of cardiovascular disease and the arteriosclerotic main cause of congee shape (Hunninghake, 2001), in addition, triglyceride (Triglycerides, TG), HDL-C (High density lipoprotein cholesterol, HDL-c) and LDL-C (Low density lipoprotein cholesterol, LDL-c) concentration and cardiovascular disease also have great correlation (Pekkanen et al., 1990; Manson et al., 1992).Cholesterol concentration in the blood can be used as a good prediction index clinically, according to u.s. national cholesterol education program (National Cholesterol Education Program, NCEP), to reach 240mg/dl be too high to T-CHOL in the definition blood, between 200 to the 239mg/dl peripheral type high blood cholesterols of then calling, be lower than 200mg/dl and then be more acceptable concentration range.Meaning is that the chance that the high person of cholesterol value suffers from the cardiovascular relevant disease will improve, and the death rate also can improve simultaneously.When the cholesterol in the blood reduces by 1%, will reduce the generation (Manson et al., 1992) of 2 ~ 3% angiocardiopathies.
In view of this, can effectively reduce cholesterol in the blood and the diet product constituent of triglyceride concentration so how to provide a kind of, be primary problem of the present invention, so this case inventor just there is generation of the present invention finally through after constantly thinking hard and studying.
Summary of the invention
Main purpose of the present invention is to provide a kind of diet product constituent with loss of weight function, and it has has apparent effect to improving blood fat matter and whole intestines.
For achieving the above object, the present invention is by the following technical solutions:
A kind of diet product constituent with loss of weight function, it is characterized in that: it is made up of lactobacillus germ (Lactobacillus plantarum) and wild type dioecism momordica root extract (Glycostate), this lactobacillus germ, be preserved in German DSMZ bacterial classification and preserve the center, the preservation address is Inhoffenstra β e 7B, 38124Braunschweig, GERMANY, preservation date is on July 15th, 2010, and deposit number is DSM23780.
Aforesaid diet product constituent with loss of weight function, preferably: the part by weight that described lactobacillus germ accounts for diet product constituent is 20～30%.
Aforesaid diet product constituent with loss of weight function, preferably: the part by weight that described wild type dioecism momordica root extract accounts for diet product constituent is 70～80%.
Aforesaid diet product constituent with loss of weight function, preferably: described diet product constituent also is added with rhamnose lactic acid bacteria (Lactobacillus rhamnosus), streptococcus thermophilus (Streptococcus thermophlius), secondary Lactobacillus casei (Lactobacillus paracasei) and fermentation lactobacillus (Lactobacillus fermentum), and constitutes compound probiotic with described lactobacillus germ.
Aforesaid diet product constituent with loss of weight function, preferably: the part by weight that described compound probiotic accounts for diet product constituent is 20～30%.
Aforesaid diet product constituent with loss of weight function, preferably: the part by weight that described wild type dioecism momordica root extract accounts for diet product constituent is 70～80%.
Beneficial effect of the present invention is:
Adopt lactobacillus germ provided by the invention (Lactobacillus plantarum) and the composition of wild type balsam pear extract (Glycostate) to carry out animal experiment, and assess its changes of weight, tests such as blood matter improvement in adipocyte size and the mouse body, after finding that lactobacillus germ mixes wild type balsam pear extraction powder, lactic acid bacteria to mouse intestinal has the effect that promotes growth really, and can improve cholesterol and triglyceride concentration in the blood, also the showing property reduction of leptin (Leptin) content, adipose tissue weight and cell size also obviously reduce, and to improving blood fat matter and whole intestines apparent effect are arranged all.
Description of drawings
Fig. 1 is the zooperal changes of weight figure of the present invention.
Fig. 2 is the analyses and comparison figure of cholesterol degradation situation of the present invention.
Fig. 3 is the analysis comparison diagram of HDL of the present invention (HDL) with low-density lipoprotein (LDL) ratio.
Fig. 4 is leptin of the present invention (leptin) analysis on Content comparison diagram.
Fig. 5 analyzes comparison diagram for the bacterium number that the present invention carries out the test of animal wastes lactic acid bacteria.
Fig. 6 carries out the analysis comparison diagram of intraabdominal adipose tissue cell size for the present invention.
The specific embodiment
The invention provides a kind of diet product constituent with loss of weight function, mainly add that by the compound probiotic that contains lactobacillus germ (Lactobacillus plantarum) wild type dioecism momordica root extract (Glycostate) forms, the part by weight that this lactobacillus germ (Lactobacillus plantarum) accounts for diet product constituent is 20～30%, and the part by weight that this wild type dioecism momordica root extract (Glycostate) accounts for diet product constituent is 70～80%; This lactobacillus germ (Lactobacillus plantarum) is preserved in German DSMZ bacterial classification and preserves the center, the preservation address is Inhoffenstra β e 7B, 38124Braunschweig, GERMANY, preservation date is on July 15th, 2010, and deposit number is DSM 23780.
Preferably, this compound probiotic is by lactobacillus germ (Lactobacillus plantarum), rhamnose lactic acid bacteria (Lactobacillus rhamnosus), streptococcus thermophilus (Streptococcus thermophlius), secondary Lactobacillus casei (Lactobacillus paracasei) and fermentation lactobacillus (Lactobacillus fermentum) are formed, and the part by weight that this compound probiotic accounts for diet product constituent is 20～30%, and the part by weight that this wild type dioecism momordica root extract (Glycostate) accounts for diet product constituent is 70～80%.
Below, with experimental example collocation experimental result picture, further specify the present invention and attainable effect thereof.
Improve the animal vivo test of blood fat matter
(1) feeding has been induced the mouse of hypercholesterolemia:
The male mice of the C57BL6/J strain that experiment is used is available from national animal used as test breeding and research center.7 ~ 8 weeks are big, random packet, and 6 every group, feed the mouse cage (IVC) in independent isolating respectively, room temperature is maintained at 25 ℃, and regularly illumination in 12 hours and dark; Feed and aseptic reverse osmosis water all leave freely to get food, and during the conforming an of week, the feed of institute's feeding be the AIN-93 standard recipe (Manufactured by MP Biomedicals Inc., France), but the feed of feeding heterogeneity ratio then after the grouping, describe in detail as after.
(2) bring out hypercholesterolemia and treatment grouping:
Raise the feed formula of week back experiment feeding mainly based on AIN-76, its composition comprises: casein, cornstarch, corn oil, cellulosic, mineral mixture, vitamin mixtures, sucrose, cholesterol and cholic acid etc., each group all is increased to the soybean oil ratio 15% and add 0.5% cholesterol, to bring out hypercholesterolemia, the feeding high cholesterol time was 4 weeks, then carry out the treatment in 2 weeks, be that experimental group is added lactic acid bacteria freeze drying powder or wild type balsam pear extraction feed or both and is mixed in the standard feed, irritate each mouse of organizing of feeding once in set time every day pipe again, mouse is in average 25g, and every feeding dosage is 15mg.The feed of institute's feeding all is stored in 4 ℃ of refrigerators, and changes fresh feed and sterilized water every day.Be grouped as follows:
A: the mouse of negative control group (Negative control group)---this group only feeding is added cholesterol feed.
B: Cholestyramine (cholestyramine) clinical medicine of interpolation 2% namely contains the cholestyramine clinical medicine of 0.3mg approximately in the feed of the mouse of medicine control group---this group among the feeding dosage 15mg every every day in feed.
C: wild type balsam pear extraction powder group---balsam pear is extracted powder make an addition in the feed, concentration is 40%.The balsam pear extraction powder that namely contains 6mg every every day among the feeding dosage 15mg approximately.
D: compound probiotic group---only with 10
10The freeze drying powder of the compound probiotic of the present invention of CFU/g, making its final concentration is 1 * 10
10CFU/g also does suitable adjustment with the cornstarch of AIN-93 standard recipe, contains the compound probiotic freeze drying powder of 1.5mg among the feeding dosage 15mg approximately every every day.
E: experimental group of the present invention---by compound probiotic (10 of the present invention
10CFU/g)+wild type balsam pear extraction powder makes an addition in the feed and forms, and in this experimental example, contains the compound probiotic freeze drying powder of 1.5mg and the balsam pear extraction powder of 6mg among the feeding dosage 15mg every every day.Preferably, the part by weight of compound probiotic freeze drying powder and balsam pear extraction powder is: compound probiotic freeze drying powder accounts for 20～30%, and dioecism momordica root extraction powder accounts for 70～80%.
(3) check analysis project:
A. measured body weight---record the mouse body weight weekly.
The blood of b. blood analysis---collection is with the 3000rpm low-speed centrifugal after 10 minutes, is frozen in-80 ℃ at once after drawing upper serum, up to carry out cholesterol and HDL, LDL analyzes, and calculates the HDL/LDL ratio.Analytical method is carried out with seralyzer, and leptin is then analyzed with ELISA kit (ELISA kit).
C. analyze in the ight soil and each compound probiotic distribution scenario partly of enteron aisle with deposit viable count---in feeding after 2 all treatments phases, collect the ight soil of respectively organizing every mouse, carry out serial dilution with suitable aseptic PBS after weighing, analyze lactic acid bacteria bacterium number with Rogosa agar again.In addition, with the mouse of feeding compound probiotic group, select 3 at random with the cervical vertebra exclusion, each section of clip digestion position comprises stomach, little intestinal segment, large intestine and caecum section fast.The homogeneous fragmentation of organizing with the aseptic PBS of 200 times of weight ratios behind the weighing respectively fully disengages the bacterium in the digestion bacterium road, and lactic acid bacterial count is carried out in serial dilution at last.
D. adipose tissue analysis---modify after the method for analytical method with reference to people such as Hirsch (1968).Take out with osmium tetroxide (osmium tetroxide) intraabdominal adipose tissue fixing, membrane filtration paper with 250 μ m filters again, and wash to remove connective tissue with PBS, and then with 25 μ m filtrate is removed, and make cell fixation on filter paper, size and the record of 100 adipocytes of random observation.
(4) biometrics:
Each analysis project in the present embodiment all carries out triple retrials and tests, experimental result is wrapped in SPSS 10.0 softwares carries out statistical analysis in the computer, all analyze (one way ANOVA through unidirectional change side earlier, analysis of variance) whether the calibrating Treatment Effects has apparent difference, measure the difference between each group with the changeable territory of Deng Kenshi test (Duncan ' s multiple range test) again, the criterion of showing property difference is p＜0.05, and experimental result is mapped with SigmaPlot 10.0 softwares.
(5) raw-food material is tested inhibitory action of the present invention:
Utilize agar diffusion method (Well-agar diffusion method) to carry out the bacteriostasis assessment of lactic acid bacterial liquid, step is with reference to the method for Lin et al. (2006).Agar-the culture medium (MRS agar, Difco company) of sterilization is poured in the Micro-Organism Culture Dish, waited to solidify the back and get the hole of diameter 7mm with sterile glass tube at culture dish, the compound probiotic liquid of the present invention with cultivation overnight is diluted to about 10 again
7Cfu/mL evenly is applied on the culture dish with aseptic cotton rod, treats that the dried a little back of bacterium liquid adds 100 μ L various raw-food materials soluble in water (10%) in hole, is sure not to make the bacterium hydrorrhea to go out and causes error.Each sample carries out three repetitions, at last the culture plate front is positioned over 37 ℃ of incubators, measures its antibacterial circle diameter size after 16 ~ 18 hours.
(6) stability in storage test:
After the wild type balsam pear extracts powder (Glycostate) and compound probiotic powder of the present invention mixes, the phenomenon that shows the unrestraint lactic acid bacteria, therefore, with wild type balsam pear extraction powder (Glycostate) 10% and compound probiotic powder 10% of the present invention, add compounds such as 80% cornstarch, be respectively charged in the serum bottle and locking, then lucifuge is stored in 4 ℃ of refrigerators and the room temperature (25 ± 3 ℃), and in 37 ℃ the baking oven, in the 0th and 30 day lay up period, the sampling analysis lactic acid bacteria was deposited viable count.
Experimental result:
(1) mouse measured body weight:
Record the mouse body weight weekly.The result shows medicine group and experimental group of the present invention after 2 weeks for the treatment of as shown in Figure 1, and the negative control group of body weight has apparent the phenomenon that reduces.The phenomenon that wild type balsam pear extraction powder group also has body weight to reduce is showing difference but statistics goes up nothing.
(2) blood analysis:
The experimental result that blood fat matter is analyzed shows the cholesterol degradation best results 36.2% of feeding medicine group as shown in Figures 2 and 3; Secondly be experimental group of the present invention, reach 30.8%, and the cholesterol of the mouse of feeding compound probiotic group also there is apparent property reduction phenomenon merely, reaches 26.6%.Aspect the ratio of HDL and LDL cholesterol, find that the HDL/LDL ratio of feeding medicine group and experimental group of the present invention all has higher phenomenon.Leptin is also found to throw drug therapy and lactic acid bacteria and is given group obvious reduction phenomenon is all arranged, as shown in Figure 4.On the whole, the present invention has preferable lipid-lowering effect by the combination formula of compound probiotic+wild type balsam pear extraction powder, therefore proves that both have cooperative effect.
(3) reach each lactic acid bacteria distribution scenario partly of enteron aisle in the analysis ight soil and deposit viable count:
Be the viable count of depositing of analyzing lactic acid bacteria in the ight soil by following table one and Fig. 5, by the result clear and definite treat 2 week back feeding lactic acid bacterias as can be known respectively organize mouse, lactic acid bacteria bacterium number in its ight soil is apparently higher than the group of no lactic acid bacteria feeding, and can be known by Fig. 5 and to find out that compound probiotic of the present invention has extremely good whole intestines effect, analyze ight soil bacterium number and can reach 9Log CFU/g.In addition, analyze each position digestive organs of mouse, find that compound probiotic of the present invention has high concentrations of viable in large intestine and caecum position.
The ight soil lactic acid bacteria bacterium number of table one, mouse treatment 2 all backs mouse is analyzed
| Before the feeding sample (the 4th week) | |
|
| Negative control group | 7.0±0.3 | 7.4±0.1 |
| The medicine control group | 7.8±0.1 | 6.8±0.3 |
| Wild type balsam pear extraction powder group | 7.5±0.2 | 7.2±0.3 |
| The compound probiotic group | 7.8±0.2 | 9.0±0.3 |
| Experimental group | 8.1±0.3 | 8.8±0.4 |
(4) adipocyte analysis:
Adipocyte calculates its size with microscopic examination and with engineer's scale, shows that feeding medicine group and lactic acid bacteria group has the less phenomenon of adipocyte volume, and 100 cells are carried out statistical analysis, and experimental result as shown in Figure 6.
(5) raw-food material is to the inhibitory action analysis of lactic acid bacteria:
Select common making an addition in the commercially available prod at present for use, demand has wild type balsam pear extraction powder, camellia extraction powder, hawthorn extraction powder and the aloe extraction powder of norcholesterol effect, test is to the influence of lactic bacteria activity behind water Hui Rong, the result shows to mix wild type balsam pear extraction powder and hawthorn extraction powder to the phenomenon of lactic acid bacteria unrestraint lactobacter growth shown in following table two.
Table two, different material extract powder to the inhibitory action of compound probiotic of the present invention
Note: the hole diameter on the culture medium is 7mm.The no any lactic acid bacteria inhibiting growth phenomenon of "-" expression.
(6) stability in storage analysis of experiments:
After bacterium powder and wild type balsam pear extraction powder or hawthorn extraction powder mix, carry out different temperatures stored in 30 days, the result is in shown in the following table three, it is optimal that the result is presented at 4 ℃ storage condition, activity does not almost have the reduction phenomenon, secondly is 25 ℃ of room temperature storage, and under 37 ℃ of environment, the bacterial strain activity significantly reduces, so be not suitable for high-temperature storage.
After the dried powder of table three, experimental group of the present invention and different material extraction powder mixes, at the shakedown analysis table of different temperatures storage
To sum up experiment as can be known, the diet product constituent with loss of weight function that the present invention is made up of compound probiotic and wild type dioecism momordica root extract (Glycostate), really can bring into play synergy and the degraded of promotion blood cholesterol levels, and leptin content is also relatively low, the ratio of HDL/LDL then improves, and shows that the present invention can effectively improve the ratio of cholesterol.The adipose tissue of observing the abdominal cavity is again found the size of adipocyte, and the adipocyte of feeding lactic acid bacteria group also has obviously less.
Therefore, generally speaking, the diet product constituent that the present invention has the loss of weight function has quite good whole intestines effect, and can be present in the alimentary canal different parts, and then can accelerate degraded and the discharge of cholesterol, therefore effectively improves blood fat matter.
And, the present invention more can be by freezing embedding dry technology, strengthen its acidproof usefulness, have cholate tolerance and strong adsorption capacity again, therefore can arrive at by the hydrochloric acid in gastric juice test smoothly that enteron aisle is being decided and hyperplasia, finally reach the Expected Results of whole intestines and norcholesterol, and find that in experimental result the compound probiotic that utilization of the present invention contains lactobacillus germ (Lactobacillus plantarum) mixes storage with wild type balsam pear extract (Glycostate), under 25 ℃ and 4 ℃ of conditions of storage, it is relatively stable that bacterium is counted activity, therefore more can be in order to make related preparations or diet product such as pulvis or capsule.
The announcement of the above each embodiment only in order to the present invention to be described, is not in order to limit the present invention, so the displacement of the change of every numerical value or equivalence must be subordinate to category of the present invention.
And by after the above detailed description, can make those skilled in the art understand that the present invention can reach aforementioned purpose really, and the present invention compares down with this series products again has apparent progressive, and the real regulation that has met Patent Law is so this case inventor files an application at this point.
Claims (6)
1. diet product constituent with loss of weight function, it is characterized in that: it is made up of lactobacillus germ and wild type dioecism momordica root extract, this lactobacillus germ, be preserved in German DSMZ bacterial classification and preserve the center, the preservation address is Inhoffenstra β e 7B, 38124Braunschweig, GERMANY, preservation date is on July 15th, 2010, and deposit number is DSM 23780.
2. the diet product constituent with loss of weight function as claimed in claim 1, it is characterized in that: the part by weight that described lactobacillus germ accounts for diet product constituent is 20～30%.
3. have the diet product constituent of loss of weight function according to claim 1, it is characterized in that: the part by weight that described wild type dioecism momordica root extract accounts for diet product constituent is 70～80%.
4. the diet product constituent that has the loss of weight function according to claim 1, it is characterized in that: described diet product constituent also is added with rhamnose lactic acid bacteria, streptococcus thermophilus, secondary Lactobacillus casei and fermentation lactobacillus, and constitutes compound probiotic with described lactobacillus germ.
5. the diet product constituent as having the loss of weight function as described in the claim 4, it is characterized in that: the part by weight that described compound probiotic accounts for diet product constituent is 20～30%.
6. the diet product constituent as having the loss of weight function as described in the claim 4, it is characterized in that: the part by weight that described wild type dioecism momordica root extract accounts for diet product constituent is 70～80%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102086347A CN103190609A (en) | 2012-01-04 | 2012-06-19 | Food composition having function of weight reduction |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210001251 | 2012-01-04 | ||
| CN201210001251.2 | 2012-01-04 | ||
| CN2012102086347A CN103190609A (en) | 2012-01-04 | 2012-06-19 | Food composition having function of weight reduction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103190609A true CN103190609A (en) | 2013-07-10 |
Family
ID=48713575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012102086347A Pending CN103190609A (en) | 2012-01-04 | 2012-06-19 | Food composition having function of weight reduction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103190609A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103598594A (en) * | 2013-10-28 | 2014-02-26 | 天津科技大学 | Application of lactobacillus plantarum in reducing blood fat and assisting fat-reducing |
| CN107302997A (en) * | 2016-04-19 | 2017-10-31 | 林秀霞 | A kind of composition for suppressing lipopexia and application thereof |
| CN109699756A (en) * | 2017-02-02 | 2019-05-03 | 中创寰宇生物科技有限责任公司 | Use of balsam pear seed oil for producing a composition for simulating sports effects |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008259498A (en) * | 2007-03-16 | 2008-10-30 | Sunstar Inc | Saccharometabolism-improving food composition and/or visceral fat reducing food composition |
| KR20100092786A (en) * | 2009-02-13 | 2010-08-23 | 대선주조 주식회사 | Multi-type antidiabetic food compound by lactobacillus fermented of natural bitterness compound from ganoderma lucidum, bitter melon and bitter buckwheat and preparing method of the same |
| TW201132348A (en) * | 2010-03-25 | 2011-10-01 | Pro Md Biotech Co Ltd | Lactobacillus sp. PM308 composition and its use for treating obesity, ameliorating endomorph body type, decreasing body fat ratio and reducing cholesterol |
-
2012
- 2012-06-19 CN CN2012102086347A patent/CN103190609A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008259498A (en) * | 2007-03-16 | 2008-10-30 | Sunstar Inc | Saccharometabolism-improving food composition and/or visceral fat reducing food composition |
| KR20100092786A (en) * | 2009-02-13 | 2010-08-23 | 대선주조 주식회사 | Multi-type antidiabetic food compound by lactobacillus fermented of natural bitterness compound from ganoderma lucidum, bitter melon and bitter buckwheat and preparing method of the same |
| TW201132348A (en) * | 2010-03-25 | 2011-10-01 | Pro Md Biotech Co Ltd | Lactobacillus sp. PM308 composition and its use for treating obesity, ameliorating endomorph body type, decreasing body fat ratio and reducing cholesterol |
Non-Patent Citations (2)
| Title |
|---|
| 朱立涵: "《乳酸菌发酵之山苦瓜牛奶豆浆与枸杞牛奶豆浆预防动脉粥状硬化之评估》", 《华艺线上图书馆》 * |
| 袁飞连，等: ""活性乳酸菌苦瓜饮料的研制"", 《江西食品工业》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103598594A (en) * | 2013-10-28 | 2014-02-26 | 天津科技大学 | Application of lactobacillus plantarum in reducing blood fat and assisting fat-reducing |
| CN107302997A (en) * | 2016-04-19 | 2017-10-31 | 林秀霞 | A kind of composition for suppressing lipopexia and application thereof |
| CN109699756A (en) * | 2017-02-02 | 2019-05-03 | 中创寰宇生物科技有限责任公司 | Use of balsam pear seed oil for producing a composition for simulating sports effects |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105343133B (en) | A kind of compound probiotic that treating ulcerative colitis, drug and preparation method thereof | |
| CN112501046B (en) | Lactobacillus fermentum with weight-losing function and application thereof | |
| CN111254090B (en) | Lactobacillus reuteri with weight losing function and application thereof | |
| CN102031229B (en) | Lactobacillus plantarum with gastrointestinal adsorption capacity and cholesterol removing capacity | |
| CN105985918B (en) | Anti-obesity lactic acid bacteria strain and application thereof in food composition and medical composition | |
| CN113913346B (en) | Lactobacillus paracasei JN-1 and application thereof | |
| Hou et al. | Beneficial effects of mung bean seed coat on the prevention of high-fat diet-induced obesity and the modulation of gut microbiota in mice | |
| CN116286551B (en) | Application of bifidobacterium longum subspecies infantis in regulating in-vivo fat metabolism, shaping, reducing fat and improving obesity | |
| Owaga et al. | Oral toxicity evaluation of kefir-isolated Lactobacillus kefiranofaciens M1 in Sprague–Dawley rats | |
| Huang et al. | Polysaccharides from soybean residue fermented by Neurospora crassa alleviate DSS-induced gut barrier damage and microbiota disturbance in mice | |
| CN103190609A (en) | Food composition having function of weight reduction | |
| Jeong et al. | Effect of fermented medicinal plants (Gynura Procumbens, Rehmannia Glutinosa, Scutellaria Baicalensis) as alternative performance enhancers in broilers | |
| Zhang et al. | Immunomodulatory and antitumor activities of the exopolysaccharide produced by potential probiotic Lactobacillus plantarum YW11 in a HT-29 tumor-burdened nude mouse model | |
| CN116555102B (en) | Lactobacillus plantarum producing gamma-aminobutyric acid, sleep-aiding probiotic composition and preparation method thereof | |
| Ahmed et al. | Hypocholesterolaemic effect of probiotic yogurt enriched with barley β-glucan in rats fed on a high-cholesterol diet | |
| Hekmat et al. | Microbial properties of probiotic fermented milk supplemented with ginseng extracts | |
| TW201322928A (en) | Dietary stuff composition with weight reduction function | |
| KR101809616B1 (en) | A probiotic strain from kefir with anti-obesity effect | |
| CN113967243B (en) | Fermented traditional Chinese medicine preparation for preventing and treating diarrhea of poultry and preparation method thereof | |
| WO2023275293A1 (en) | Physiologically acceptable yeast compositions and uses thereof | |
| CN103142657A (en) | Application of bacteroides fragilis in preparing composition for preventing and treating hypercholesteremia | |
| Ivanovna et al. | Influence of biologically active substances from Kombucha ( Medusomycesgisevii) on rat gut microbiota with experimental antibiotic-associated dysbiosis | |
| KR20180016164A (en) | Method for manufacturing fermentation mixture of dietary fiber and lactic acid bacteria | |
| CN116076569A (en) | Use of MN-Gup for the preparation of a dairy product for preventing or alleviating obesity or weight gain | |
| CN105394586A (en) | Natto composition with functions of regulating intestinal tracts and regulating immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130710 |